Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PALISADE BIO, INC. Director's Dealing 2024

Feb 13, 2024

35274_dirs_2024-02-13_d3ea0491-e42c-4e80-b725-a758266be5f5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PALISADE BIO, INC. (PALI)
CIK: 0001357459
Period of Report: 2024-02-08

Reporting Person: Diaz Stephanie (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-08 Common Stock, par value $0.01 M 6980 $0.00 Acquired 6980 Direct
2024-02-08 Common Stock, par value $0.01 M 5820 $0.00 Acquired 12800 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-08 Restricted Stock Units $ M 6980 Disposed Common Stock (6980) Direct
2024-02-08 Restricted Stock Units $ M 5820 Disposed Common Stock (5820) Direct
2024-02-08 Common Stock Options $1.60 M 9580 Disposed 2033-06-11 Common Stock (9580) Direct
2024-02-08 Common Stock Options $1.60 M 9580 Acquired 2033-06-11 Common Stock (9580) Direct
2024-02-08 Common Stock Options $0.59 M 6880 Disposed 2033-11-21 Common Stock (6880) Direct
2024-02-08 Common Stock Options $0.59 M 6880 Acquired 2033-11-21 Common Stock (6880) Direct

Footnotes

F1: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on June 11, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors.

F2: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units granted on November 21, 2023, resulting from the full accelerated vesting in connection with Reporting Person's resignation from the Issuer's Board of Directors.

F3: This restricted stock unit was granted on June 11, 2023 and pursuant to the issuance upon full vesting as described in Footnote 1, is no longer outstanding.

F4: This restricted stock unit was granted on November 21, 2023 and pursuant to the issuance upon full vesting described in Footnote 2, is no longer outstanding.

F5: Each restricted stock unit represents the right to receive one share of common stock.

F6: Each option represents the right to purchase one share of common stock at the exercise price.

F7: Represents the modification of the option granted on June 11, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors.

F8: Represents the modification of the option granted on November 21, 2023, resulting in (i) immediate vesting in full of the outstanding grant and (ii) extension of the exercise period until the expiration date in connection with Reporting Person's resignation from the Issuer's Board of Directors.